page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Mild Dysplasia

Mild dysplasia means the skin cells of the cervix are reproducing slightly more quickly than normal. The cells are slightly more plump than they should be and have larger, darker nuclei. This is not cancer, but does have some pre-malignant potential in some women. Other phrases that describe mild dysplasia include:

mild dysplasia
Initial normal appearance of mild dysplasia

mild dysplasia
Mild Dysplasia after application of acetic acid

mild dysplasia
Mild Dysplasia

after treatment with LEEP
Cervix immediately after LEEP

Many factors contribute the development of mild dysplasia, but infection with HPV, (Human Papilloma Virus) is probably the most important. Immune system impairment may also contribute.

Mild dysplasia is not a permanent feature once it occurs. It can come and go, being present on a woman's cervix (and Pap smear) at one time and not another. This happens  because the HPV virus that is a pre-requisite for these changes can lie dormant within the cervical skin cells. Normally held in check by the woman's immune system, the HPV can, at times of immune system distraction, reactivate the cellular machinery that leads to more rapid growth.

For women who develop a single Pap smear showing mild dysplasia, there are basically three approaches that are commonly followed:

  1. Repeat Pap in 6 months. If the dysplasia persists or worsens, further evaluation is undertaken. If the Pap returns to normal, the woman is followed with more frequent Pap smears. Ultimately, the frequency of Pap smear screening returns to normal, if there is no further evidence of dysplasia. The primary advantage of this approach is it limits the number of women needing colposcopy. Particularly among adolescent women, most of these Pap abnormalities will prove to be self-limited HPV infections. Repeating the Pap allows for many of these cervices to heal, avoiding more extensive intervention. The primary disadvantages of the repeat Pap approach are that the majority of these women will ultimately need colposcopy anyway and they have been subjected to varying degrees of anxiety over known, but unresolved health issues.

  2. Immediate Colposcopy. Some physicians feel that the cervix should be evaluated with colposcopy with even a single dysplastic Pap smear. Their reasoning is that while many of the Pap smears (about half) revert to normal in 6 months, the abnormality will often re-appear at a later, less convenient time. They also reason that many women will feel anxiety over simply observing the abnormality over time and not investigating it right away. The primary disadvantage to this approach is that even women with falsely positive Pap smears will undergo a moderately costly evaluation.

  3. See and Treat. Rather than colposcopic evaluation and directed biopsies, followed by some form of treatment a few days or weeks later, some physicians prefer to evaluate the cervix with the colposcope, then immediately perform a LEEP procedure at the same time, for those in whom the LEEP is appropriate. Their rationale is that the combined see-and-treat is more cost-effective, it provides an excellent specimen, and is typically highly effective treatment. Its primary drawbacks are: It is a relatively costly procedure, requiring more advanced skills and equipment not always available in all GYN offices, and is overtreatment for most of those seen. For this reason, many gynecologists reserve the see-and-treat approach for those whose Pap smears show more advanced lesions.

One common method of treatment of mild dysplasia is cryosurgery (freezing the part of the cervix containing the dysplastic cells and destroying those cells). Other approaches include vaporizing the dysplastic cells with a laser, or shaving them off with an electrified wire (LEEP). Sometimes, with very limited areas of dysplasia, the process of biopsy of that area removes enough tissue that the remaining dysplasia is sloughed off in the resulting eschar.

In years past, we would often treat everyone with mild dysplasia vigorously to try to prevent progression to cancer. We had good results in about 90% of those treated. Unfortunately, all of the treatment modalities had about a 10% recurrence rate, not much different than if we had not treated them at all.

If not treated, about 10% of women who develop mild dysplasia, will demonstrate a slow progression to moderate, then severe dysplasia, and ultimately develop invasive cancer of the cervix. This process generally takes about 10 years, although occasionally it can progress much more rapidly. The remaining 90% will either remain unchanged at mild dysplasia or regress back to normal.

Currently, we usually just observe women with mild dysplasia with frequent Paps (every 3-6 months) over the next year or two, to discern those who will progress (the few) from those who remain unchanged or regress (the many). Those showing signs of advancement are then treated. This is based on the principles that:

  1. Most cases of mild dysplasia regress.

  2. Those that advance will do so slowly enough that we can detect it.

  3. Treatment of dysplasia earlier gives no better results than treatment later.

  4. While the risks associated with treatment are small, they are not negligible, so it is better to reserve treatment for those who really need it.

There are plenty of exceptions to this general approach. Women whose access to medical care at a later time could be limited may benefit from more aggressive treatment. Those whose dysplasia covers an unusually wide area or whose lesion remains relatively inaccessible may also need to be treated.

For women who have previously been evaluated with colposcopy and found to have dysplasia, the appearance of mild dysplasia on a subsequent Pap smear is not particularly alarming. Whether to re-colposcope them and the timing of such a re-evaluation must be individualized, based on the patient's history, risk factors, the degree of abnormality in the past and intervening Pap smear results.


Military Obstetrics & Gynecology
© 2003, 2004, 2005, 2006 Medical Education Division, Brookside Associates, Ltd.
All rights reserved


This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo





Advertise on this site